294 results on '"Lee, Byron H."'
Search Results
2. Exploring the utility of snRNA-seq in profiling human bladder tissue: A comprehensive comparison with scRNA-seq
3. Oncological Outcomes for Patients with European Association of Urology Very High-risk Non–muscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Guérin or Early Radical Cystectomy
4. Comparing Pathologic and Survival Outcomes Between Primary and Secondary Muscle Invasive Bladder Cancer When Treated by Radical Cystectomy With or Without Neoadjuvant Chemotherapy
5. Single-cell and spatial mapping Identify cell types and signaling Networks in the human ureter
6. Neighborhood Socioeconomic Disadvantage Associated With Increased 90-Day Mortality Following Radical Cystectomy
7. An exploratory study investigating the impact of the bladder tumor microbiome on Bacillus Calmette Guerin (BCG) response in non-muscle invasive bladder cancer
8. Comparison of Oncologic Outcomes Following Open and Robotic-assisted Radical Cystectomy with both Extracorporeal and Intracorporeal Urinary Diversion
9. Oncologic outcomes of intravesical therapy in the management of nonmuscle invasive bladder cancer with variant histology
10. Intracorporeal Urinary Diversion in Robotic Radical Cystectomy
11. Single-cell RNA sequencing analysis identifies acute changes in the tumor microenvironment induced by interferon α gene therapy in a murine bladder cancer model.
12. DNA Methylation Regulates Alternative Polyadenylation via CTCF and the Cohesin Complex
13. MP16-08 CHALLENGING THE PARADIGM OF “BCG UNRESPONSIVE” BLADDER CANCER: DOES ADDITIONAL BCG HAVE AN EFFECT?
14. PD30-08 ELUCIDATING THE RESPONSE RATES TO CONTINUED BACILLUS CALMETTE-GUERIN (BCG) IN PATIENTS WITH BCG EXPOSED BLADDER CANCER: IMPLICATIONS FOR CLINICAL TRIAL DESIGN
15. ONCOLOGIC OUTCOMES OF INTRAVESICAL THERAPY IN THE MANAGEMENT OF NON-MUSCLE INVASIVE BLADDER CANCER WITH VARIANT HISTOLOGY
16. Challenging the Paradigm of “BCG-unresponsive” Bladder Cancer: Does Additional Bacillus Calmette-Guérin Have an Effect?
17. The role of enhanced recovery after surgery protocols in the development of acute kidney injury following radical cystectomy
18. Orthotopic urinary diversions after radical cystectomy for bladder cancer: lessons learned last decade
19. Intratumoral heterogeneity of ERBB2 amplification and HER2 expression in micropapillary urothelial carcinoma
20. Validation of a Postoperative Nomogram Predicting Recurrence in Patients with Conventional Clear Cell Renal Cell Carcinoma
21. Ability of the surgical Apgar score to predict acute kidney injury following radical cystectomy
22. 5mC: what goes on must come off
23. Survival outcomes following radical cystectomy in patients with prior pelvic radiation for prostate cancer: A matched cohort analysis
24. Oncologic outcomes of intravesical therapy in the management of nonmuscle invasive bladder cancer with variant histology
25. Heat shock induces alternative polyadenylation through dynamic DNA methylation-regulated chromatin looping
26. Comparison of renal function after open radical cystectomy, extracorporeal robot assisted radical cystectomy, and intracorporeal robot assisted radical cystectomy
27. Abstract 4733: Effect of KDM6A mutation in bladder cancer
28. Methylome-wide Sequencing Detects DNA Hypermethylation Distinguishing Indolent from Aggressive Prostate Cancer
29. Renal function recovery after radical nephroureterectomy for upper tract urothelial carcinoma
30. Changing Landscape of Prostate Cancer Favoring Low-Risk Prostate Cancer: Implications for Active Surveillance Versus Focal Therapy
31. Supplementary Table and Figures from Transcriptomic and Protein Analysis of Small-cell Bladder Cancer (SCBC) Identifies Prognostic Biomarkers and DLL3 as a Relevant Therapeutic Target
32. Supplementary Data 1 from KDM6A Loss Triggers an Epigenetic Switch That Disrupts Urothelial Differentiation and Drives Cell Proliferation in Bladder Cancer
33. Supplementary Figure 1 from KDM6A Loss Triggers an Epigenetic Switch That Disrupts Urothelial Differentiation and Drives Cell Proliferation in Bladder Cancer
34. Supplementary Data 2 from KDM6A Loss Triggers an Epigenetic Switch That Disrupts Urothelial Differentiation and Drives Cell Proliferation in Bladder Cancer
35. Supplementary Figure 2 from KDM6A Loss Triggers an Epigenetic Switch That Disrupts Urothelial Differentiation and Drives Cell Proliferation in Bladder Cancer
36. Supplementary Figure 4 from KDM6A Loss Triggers an Epigenetic Switch That Disrupts Urothelial Differentiation and Drives Cell Proliferation in Bladder Cancer
37. Supplementary Figure 5 from KDM6A Loss Triggers an Epigenetic Switch That Disrupts Urothelial Differentiation and Drives Cell Proliferation in Bladder Cancer
38. Supplementary Figure 7 from KDM6A Loss Triggers an Epigenetic Switch That Disrupts Urothelial Differentiation and Drives Cell Proliferation in Bladder Cancer
39. Supplementary Figure Legends from KDM6A Loss Triggers an Epigenetic Switch That Disrupts Urothelial Differentiation and Drives Cell Proliferation in Bladder Cancer
40. Supplementary Figure 3 from KDM6A Loss Triggers an Epigenetic Switch That Disrupts Urothelial Differentiation and Drives Cell Proliferation in Bladder Cancer
41. Supplementary Table S1 from KDM6A Loss Triggers an Epigenetic Switch That Disrupts Urothelial Differentiation and Drives Cell Proliferation in Bladder Cancer
42. Supplementary Figure 6 from KDM6A Loss Triggers an Epigenetic Switch That Disrupts Urothelial Differentiation and Drives Cell Proliferation in Bladder Cancer
43. Supplementary Figure 8 from KDM6A Loss Triggers an Epigenetic Switch That Disrupts Urothelial Differentiation and Drives Cell Proliferation in Bladder Cancer
44. Supplementary Figures 1-5 from A Requirement for DICER to Maintain Full Promoter CpG Island Hypermethylation in Human Cancer Cells
45. Data from Dysregulation of Cholesterol Homeostasis in Human Prostate Cancer through Loss of ABCA1
46. Supplementary Tables 1-2 from Dysregulation of Cholesterol Homeostasis in Human Prostate Cancer through Loss of ABCA1
47. Data from A Requirement for DICER to Maintain Full Promoter CpG Island Hypermethylation in Human Cancer Cells
48. Supplementary Figures 1 - 3 from Dysregulation of Cholesterol Homeostasis in Human Prostate Cancer through Loss of ABCA1
49. Assessment of surgical complications in patients with metastatic clear cell renal cell carcinoma (mccRCC) receiving perioperative cabozantinib and nivolumab on Cyto-KIK clinical trial.
50. KDM6A Loss Triggers an Epigenetic Switch That Disrupts Urothelial Differentiation and Drives Cell Proliferation in Bladder Cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.